http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107951885-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438
filingDate 2017-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107951885-B
titleOfInvention A kind of combination of oral medication for treating capillary leak syndrome
abstract The invention belongs to field of medicaments, more particularly to a kind of combination of oral medication for treating capillary leak syndrome.By pharmaceutically acceptable pharmaceutic adjuvant and roller, smooth, tartaric acid Mo Fanselin is made the combination of oral medication of the treatment myocardial ischemia-reperfusion injury;Its middle roller is smooth and the weight part ratio of tartaric acid Mo Fanselin is:Smooth 6~25 parts by weight of roller, 3~9 parts by weight of tartaric acid Mo Fanselin.The dosage form of the combination of oral medication of the treatment capillary leak syndrome is preferably granule.Composition mesotartaric acid Mo Fanselin is smooth to roller to have synergistic effect, and roller is smooth, tartaric acid Mo Fanselin has significant decrease effect to the capillary permeability of capillary leak syndrome rat model.
priorityDate 2017-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106692094-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106692082-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450183611
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5359386
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID188338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452343182
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447315
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86598188
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84571
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449454525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527835
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10311306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409794675
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553385
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID188338
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496863
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322677
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11672491
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450235101

Total number of triples: 41.